Medcast

This MEDcast examines the role of B cells in the pathogenesis of myasthenia gravis and neuromyelitis optica spectrum disorder and how B-cell-targeted therapies are influencing clinical practice. Faculty discuss the evolution from traditional immunosuppressive approaches toward targeted biologic strategies, including considerations for treatment sequencing, steroid reduction, and earlier intervention. The discussion also highlights practical barriers to earlier use, including payer access, infusion logistics, and patient-specific considerations. Looking ahead, the faculty explore how emerging B-cell-directed approaches and growing clinical experience may further shape long-term treatment strategies in MG and NMOSD.

The discussion explores the evolving management of myasthenia gravis (MG), focusing on treatment selection, sequencing, and strategies for switching therapies in clinical practice. The expert faculty highlight how the expanding range of targeted therapies, including FcRn inhibitors, complement inhibitors, and B-cell–depleting agents, has enabled more individualized, patient-centered care, balancing short-term symptom control with long-term disease management. The panelists emphasize a shift toward earlier, proactive optimization of therapy to improve long-term outcomes and reduce disease burden in patients with MG.

Ali Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.

Panelists discuss the clinical presentation, diagnostic approaches, and treatment considerations for narcolepsy, offering practical insights to guide healthcare professionals new to its diagnosis and management.

Panelists discuss how recent advancements in Parkinson’s disease treatments and a patient-centered approach to care are essential in managing dyskinesia while improving overall symptom control.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

The neurology experts discuss the importance of early and accurate diagnosis of Parkinson’s disease, the role of alpha-synuclein in the diagnosis of synucleinopathies and approaches to implementing screening protocols in clinical practice.

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

The expert neurologists discuss non-motor symptoms of Parkinson’s disease: types, their impact on patient’s quality of life, and current and emerging treatment options for non-motor symptoms.

The neurology doctors discuss motor fluctuations and dyskinesia associated with Parkinson’s Disease.

In this episode of MEDcast, expert geriatric psychiatrists explore the urgent need for effective diagnostic methods that can detect Alzheimer’s disease at an early stage. We will discuss blood-based biomarkers and other advancements that can help screen Alzheimer’s disease non-invasively and early in the disease course.

In this episode of MEDcast, expert geriatric psychiatrist and neurologist delve into the recent advances in the treatment of Alzheimer’s dementia. We will discuss treatments that are on the cusp of FDA approval and others that are coming down the pipeline.

In this episode of MEDcast, Dr Krieger, Dr Brandstadter, and Dr Bove discuss MS care in patients who are considering pregnancy. They highlight treatment options, monitoring recommendations during and after pregnancy, as well as other crucial considerations when caring for patients with childbearing goals.

Expert geriatric psychiatrists explore a frequently encountered symptom in Alzheimer’s disease, agitation. We will discuss its impact on patient’s and care giver’s quality of life, the current standard of care and the first FDA approved agent for treatment of agitation symptoms in Alzheimer’s disease.

Dr Krieger, Dr Brandstadter, and Dr Lublin discuss the advances made in recognizing and managing multiple sclerosis over the last few decades and the challenges that remain.

In this episode of MEDcast, expert neurologists delve into anti-CD20 disease-modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS.